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Introduction: People with Down syndrome (DS) are particularly susceptible to
Alzheimer’s disease (AD) due to the triplication of the amyloid precursor protein (APP)
gene. In this cross-sectional study, we hypothesized that choroidal thinning reported in
sporadic AD (sAD) is mirrored in adults with DS.
Methods:The posterior pole of the eye for 24 adults withDS and 16 age-matched con-
trols (Ctrl) were imagedwith optical coherence tomography. Choroidal thickness (ChT)
was measured and analyzed in relation to cognitive status and cerebral amyloid beta
(Aβ) load.
Results: ChT was increased in people with DS (pwDS) compared to Ctrl. This increase
was associatedwith gender differences and positively correlatedwith cerebral Aβ load
in a small subset. There was no significant correlation detected between ChT and age
or cognitive status.
Discussion: In contrast to sAD this study found a significantly thicker choroid in pwDS.
Whether these changes are related to Aβ pathology in DS needs further investigation.
KEYWORDS
Alzheimer’s disease, biomarker, choroid, dementia, Down syndrome, enhanced depth optical
coherence tomography, posterior pole imaging
1 INTRODUCTION
People with Down syndrome (pwDS) are known to be at increased risk
of developing Alzheimer’s disease (AD) due to the trisomy of chromo-
some 21, which results in the overproduction of amyloid beta (Aβ) pro-
tein and plaque formation in the brain.1 Improved support has led to a
two-fold increase in life expectancy for pwDS resulting inADbecoming
an increasing concern.2
Because the DS population represents the largest cohort of genetic
AD, with about 6 million people worldwide, understanding early AD
biomarkers in DS is crucial for clinical studies for DS and sAD.3,4 An
increasing number of studies investigating the brain, cerebrospinal
fluid (CSF) and blood biomarkers have shown that the natural history
of AD in pwDS is very similar to those with sporadic AD (sAD)3,5–8
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As a potential early biomarker for AD, retinal thinning has been
investigated in DS. In contrast to what has been observed in sAD
or mild cognitive impairment (MCI), the retina was found to be
thicker in those with DS compared to age-matched controls9
despite the AD pathology and the accelerated aging effect
in DS.2,10
In sAD, the choroid also undergoes thinning, both in MCI11 and
later stages,12,13 as assessed in vivo using enhanced depth imaging
optical coherence tomography (EDI-OCT). It is believed that Aβ accu-
mulation in the choroid leads to inflammation, which results in neu-
rodegeneration and vascular attenuation, mirroring the evolution of
the amyloid cascade in the brain.11,13 Despite the choroid having been
proposed as a potential early and non-invasive biomarker that may
reflect neurodegeneration in thebrain, the clinical utility of imaging the
Alzheimer’s Dement. 2021;13:e12170. wileyonlinelibrary.com/journal/dad2 1 of 8
https://doi.org/10.1002/dad2.12170
2 of 8 CSINCSIK ET AL.
choroid remains inconclusive in sAD.14,15 Given that pwDS overpro-
duce Aβ, studying choroidal thickness (ChT) in adults with DS before
or during the onset of clinical dementia, may provide a better insight
into early choroidal changes due to developing AD pathology. The
only published study in the literature assessed ChT in DS in children
and adolescents and found no evidence of choroidal thinning rela-
tive to an age-matched Ctrl group.16 However, ChT has never been
assessed in adults with DS. For the first time, this cross-sectional study
investigated whether choroidal thinning reported in sAD and MCI is
mirrored in adults with DS before clinical evidence of dementia is
apparent.
2 METHODS
2.1 Study recruitment and imaging
The imaging was undertaken by trained examiners in Cambridge, UK.
The pwDS were recruited from an existing cohort.9 Age-matched con-
trols were recruited locally in Cambridge. The study was conducted
with ethical approval from the East of England Cambridge Central
Research Ethics Committee (study ref. 14 /EE/1118), and in accordance
with the World Medical Association Declaration of Helsinki. Written
informed consent was obtained from all individuals, except for those
pwDS who lacked the capacity to consent in which case advice was
sought from an identified consultee in keeping with theMental Capac-
ity Act 2005.
After pharmacological mydriasis (1% tropicamide), all participants
were imaged using the Heidelberg Spectralis OCT (Heidelberg Engi-
neering GmbH, Heidelberg, Germany, Camera Model S3610) in EDI
mode, between November 2018 and October 2019. Each foveal-
centered EDI scan consisted of 25 high resolution (1536 A scans) 9
times averagedB scans, spaced 240 μmapart, with a total scanned area
of 300 × 20◦, using Automatic Real-Time Tracking (ART) and the Retina
module (Figure 1 A1).
2.2 Choroidal segmentation
As described by Chhablani et al., manual segmentation was performed
on each of the 25 horizontal B-scans for the right eye only of each
participant using Heidelberg Eye Explorer (v.1.10.4.0).17 The Inter-
nal Limiting Membrane (ILM) segmentation line was moved to the
RPE/Bruch’s membrane interface, and the Bruch’s membrane seg-
mentation line to the inner border of the sclera–the choroidal scle-
ral interface (CSI) (Figure 1 B1 and B2). Consequently, the lines now
demarcated choroidal rather than retinal thickness. In cases where the
suprachoroidal layer (SCL) (hyperreflective suprachoroidal stroma and
hyporeflective suprachoroidal space [SCS]) was present, the inner bor-
der of the sclera was posterior to the SCS (Figure 1 C2). If the SCL
was absent, the inner border of the sclera corresponded to the inter-
face between the hyporeflective vasculature and the hyperreflective
HIGHLIGHTS
∙ This is the first study investigating ChT1 in pwDS2.
∙ Manual segmentation revealed an increased ChT1 in
pwDS2.
∙ There is an increased prevalence of suprachoroidal space
in pwDS2.
∙ Cerebral Aβ3 load correlates with ChT1 in a small subset
of pwDS2.
∙ The choroidal thickening in pwDS2 is contrary to the thin-
ning reported in sAD4.
RESEARCH INCONTEXT
1. Systematic review: Based on reviewing the available lit-
erature, using keywords, optical coherence tomography,
choroidal thickness (ChT), and Down syndrome (DS), we
identified one study assessing ChT in DS. This study
recruited children with DS and found no significant dif-
ference in ChT compared to age-matched controls. This
is appropriately cited in our manuscript.
2. Interpretation: In contrast to the thinning observed in
sporadic Alzheimer’s disease (AD), this study found a
thicker choroid in adults withDS, before the onset of clin-
ical dementia. The lack of changes in ChT in children with
DS suggesting that the thicker choroid detected in our
study is a feature of an older DS population and may be
the result of developing AD pathology.
3. Futuredirection: As this is the first time that thickeningof
the choroid is recorded in DS, further studies are needed
to verify this observation. Furthermore, it will be impor-
tant to determine whether the result is due to the devel-
oping AD pathology.
sclera (Figure 1C1). After segmentation, the averaged thickness values
of the choroid were manually recorded in micrometers for each sec-
tor of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid
with circle diameters of 1, 3, and 6 mm (Figure 1 A2). A second grader
re-segmented the single B-scan crossing the fovea for each study par-
ticipant to validate the manual segmentation. After re-segmentation,
13 measurement points were defined, one at the foveola and 500 μm
intervals from the foveola to 3 mm nasal and 3 mm temporal (ETDRS
grid size). The thickness values for each pre-defined point were manu-
ally recorded, and interobserver agreementwas calculated. In addition,
retinal thickness values were also extracted using the corresponding
posterior pole scans and ETDRS grid, as reported in,9 to assess its rela-
tionship with ChT.
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F IGURE 1 Determination of choroidal thickness in control and in people with Down syndrome. A1 and A2 show the infrared fundus image
with green lines demarcating the scanning area (A1. One of the 25 corresponding Enhanced depth imaging (EDI) Optical coherence tomography
(OCT) B-scans (1/25) is depicted in B1 and B2. The retina is outlined as a result of automated retinal segmentation (B1), and the choroid is outlined
as a result of manual segmentation (B2). The lines denoting the internal limitingmembrane (ILM) (yellow arrows) and Bruch’s membrane (BM)
(pink arrows) (B1) weremoved from their automated position to delineate the retinal pigment epithelium/Bruch’s membrane interface and the
choroid-sclera interface respectively (B2). After choroidal segmentation, the thickness values for each sector of the foveal centered Early
Treatment Diabetic Retinopathy Study (ETDRS) grid were extracted (A2) and plotted onD (Ctrl= black; pwDS= red). EDI1OCT2 B scan of the
same area of the posterior pole from a Ctrl (C1) and pwDS (C2), illustrating the suprachoroidal layer (SCL) with the hyperreflective stroma (green
arrowhead) and the suprachoroidal space (SCS) (white arrowhead). The line graph onD shows the choroidal thickness in Ctrl (black line and error
bars) and pwDS (red line and error bars). Estimatedmarginal mean values of the adjustedmodel were plotted in each group for each sector of the
ETDRS3 grid. Box andwhisker plots on E show the unadjusted individual choroidal thickness values inmales and females for both Ctrl and pwDS in
the inner circle (C), inner ring (average of SI, TI, II, and NI sectors) and outer ring (average of SO, TO, IO, NO sectors) of the ETDRS grid as well as
globally (all ETDRS sectors averaged). Abbreviations: Ctrl, control; pwDS, people with Down syndrome; SO, superior outer; SI, superior inner; TO,
temporal outer; TI, temporal inner; IO, inferior outer; II, inferior inner; NO, nasal outer; NI, nasal inner; C, inner circle. *, P< 0.05
EDI scans with missing B scans or missing parts of the CSI, with
a quality score (QS) <15 and with scan focus <−6D or >6D were
excluded, according to obvious problems (O), poor signal strength
(S), centration of scan (C), algorithm failure (A), retinal pathology
other than MS related (R), illumination (I) and beam placement (B)
(OSCAR-IB) criteria.18 Additional exclusion criteria were history of
eye surgery within 3 months of retinal imaging, intravitreal injection,
severe cataract, glaucoma, age-related macular degeneration, and dia-
betes mellitus. Presence of psychiatric illness other than dementia for
theDSgroup, or includingdementia for the control group,was a further
exclusion criterion.
2.2.1 CAMCOG-DS and CAMDEX-DS
The Cambridge Cognition Examination DS (CAMCOG-DS) was used
to assess areas of cognition known to decline with the onset of
dementia.19 The Cambridge Examination for Mental Disorders of
Older People with Down Syndrome and Others with Intellectual Dis-
abilities (CAMDEX-DS)wasused to assess changes related to theonset
of dementia retrospectively and to exclude the possibility of other dis-
orders that mimic dementia.20 PwDS did not show signs of clinical
dementia based on their CAMCOG-DS score and CMDEX-DS assess-
ment. CAMCOG-DS scoreswere available for 21 of 24DSparticipants.
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Age: y (mean [SD]) 36.31 (9.31) 38.50 (7.25) .410*
CAMCOG-DS‡ (mean [SD]) N/A 78.43 (16.08) N/A
MOF ctx§ (mean [SD]) N/A 0.287 (0.08) N/A
RMF ctx§ (mean [SD]) N/A 0.311 (0.05) N/A
Sex; male [N(%]) 7 (43.8) 15 (62.5) .243†
Imaging time; AM (N[%]) 11 (68.8) 6 (25.0) .006†
SCS; present (N[%]) 0 (0%) 14 (58.3%) .000 †
Characteristics for control and pwDS including between-group comparisons.
Bold numbers indicate a significant difference (P< 0.05).
Abbreviations: pwDS, people with Down syndrome; CAMCOG-DS, Cambridge Cognition Examination DS; AM, ante meridiem; SCS, suprachoroidal space;
MOF, medial orbitofrontal; RMF, rostral middle frontal; Ctx, cortex.
*Independent sample t test for continuous variables; †χ2 test for categorical variable; ‡CAMCOG-DS scores were available for only 21 of 24 pwDS; §Medial
orbitofrontal (MOF) and rostral middle frontal (RMF) cortex (ctx) Aβ scores were available for only 6 of 24 pwDS.
2.2.2 Brain imaging
For a sub-set of pwDS, positron emission tomography (PET) scans
were acquired in three-dimensional mode (3D) mode on a General
Electric Medical Systems Advanced PET Scanner using Pittsburgh
compound11C (PIB). Mean cortical Aβ load was calculated in all corti-
cal regions using the non-displaceable binding potential (BPND).
2.3 Statistical analysis
All analysis was conducted using SPPS (version 26.0; SPSS Inc.,
Chicago, IL) and data were visualized using GraphPad Prism (version
7). When assessing study characteristics, the chi-square test was used
for categorical variables and independent sample t test (with Levene’s
Test for Equality ofVariances) for continuous variables. The continuous
variable of ChT was normally distributed as verified by the Shapiro-
Wilk test. Multivariate linear regression adjusted for multiple compar-
isons (Bonferroni) was used to assess the relationships between ChT
of different sectors of the ETDRS grid and diagnosis (Ctrl, DS), with
Ctrl as a reference group. Similarly, multivariate linear regression was
used to assess the effect of gender on ChT within Ctrl and DS group.
The time the retinal scans were acquiredwas recorded as a categorical
variable (AM or PM) and included as a covariate in the final regression
model to address diurnal changes in ChT. The right eye was selected
as the study eye, and only data from this eye were included in the
final analysis. Symmetricity between the right and the left eyes was
assessed by paired sample t test on fovea-centered single B-scans from
both eyes.
All P values < 0.05 were considered significant. Inter-observer
agreement between the two graders was assessed by calculating intr-
aclass correlation coefficient (ICC). Pearson correlation was used to
evaluate the relationship between ChT and age, CAMCOG-DS scores,
brain Aβ load, and retinal thickness.
3 RESULTS
3.1 Cohort characteristics
There was no significant difference in age or gender ratio between DS
and Ctrl groups (Table 1). The mean CAMCOG-DS score was 78.43,
with a standard deviation of± 16.08 (Table 1).
3.2 There are significant changes in the choroid
in pwDS
To assess the reliability of the manual segmentation, inter-rater agree-
ment was calculated using ICC and was found to range from 0.88 to
0.97, falling in the good-excellent correlation range. ChT values were
not significantly (p > 0.05) different between the right and left eyes
(Figure S1).
In pwDS, regional differences in ChT across the posterior pole were
very similar to the pattern of regional differences measured in the Ctrl
group (Figure 1 D). The choroid was thinnest in the nasal outer (NO)
and thickest in the superior inner (SI) sectors in both pwDS and Ctrls
(Figure 1 D and Table S1). When ChT values were compared between
the two groups, apart from the inferior inner (II) sector, a significantly
increased ChT was detected across all the sectors of the ETDRS grid
in pwDS compared to the Ctrls (Table S1). In the final adjusted model,
the differences remained significant in all sectors except in II and IO
(Figure 1 D and Table S1).
When gender differences were assessed, a significantly (P < 0.05)
thicker choroid was found in males compared to females in the inner
circle (C;M: 414.60±98.02 μmvs F: 292.11±97.07 μm), the inner ring
(average of SI, TI, II and NI sectors; M: 394.61 ± 97.25 μm vs F: 293.38
± 96.13 μm), and globally (M: 378.14 ± 94.11 μm vs F: 288.63 ± 93.64
μm) in pwDS (Figure 1E and Table S2). Significant differences were not
observed in Ctrl (P> 0.05) (Figure 1E and Table S2).
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ChT Age CAMCOG AβMOF ctx AβRMF ctx
Superior Outer −.034 (.902) −.130 (.545) .304 (.181) .778 (.069) .786 (.064)
Temporal Outer .300 (.258) −.255 (.230) .186 (.419) .966 (.002) .957 (.003)
Inferior Outer −.041 (.882) −.227 (.286) .062 (.791) .740 (.093) .773 (.071)
Nasal Outer −.225 (.402) −.343 (.101) .095 (.683) .840 (.036) .831 (.040)
Superior Inner −.046 (.866) −.222 (.297) .371 (.098) .648 (.164) .730 (.100)
Temporal Inner .216 (.422) −.216 (.310) .326 (.149) .897 (.015) .861 (.028)
Inferior Inner −.033 (.905) −.251 (.237) .249 (.277) .880 (.021) .928 (.008)
Nasal Inner −.045 (.868) −.330 (.115) .227 (.322) .925 (.008) .939 (.005)
Inner Circle .187 (.489) −.293 (.165) .308 (.174) .913 (.011) .902 (.014)
Centre (SF) .261 (.329) −.271 (.200) .319 (.158) .903 (.014) .855 (.030)
Global .066 (.808) −.264 (.212) .261 (.253) .927 (.008) .936 (.006)
Assessing the relationships between the choroidal thickness of different sectors of the early treatment diabetic retinopathy study (ETDRS) grid and age,
CambridgeCognition ExaminationDS (CAMCOG-DS), medial orbitofrontal (MOF), and rostralmiddle frontal (RMF) cortex (ctx) Aβ load. P valueswere calcu-
lated using the Pearson correlation. Bold numbers indicate a significant correlation (P < 0.05). Abbreviations: ChT, choroidal thickness; Ctrl, control; pwDS,
people with Down syndrome; r, Pearson correlation coefficient; P, P-value; SF, subfoveal; MOF, medial orbitofrontal; RMF, rostral middle frontal; ctx, cortex;
Aβ, amyloid beta.
The SCS (a hyporeflective band in the SCL) was visible in 14 DS par-
ticipants (58.3%) but in none of the controls (Table 1 and Figure 1 C2).
Those with visible SCS were significantly older (41.6 ± 6.7 years, P =
.019) than those in whom the SCS was not visible (35.4 ± 8 years).
The visibility of the SCS was not associated with increased ChT in DS
(Global ChT, SCS not present: 349.9 ± 128 vs SCS present: 340.7 ±
83.7, P= 0.843).
3.3 There is a correlation between ChT and
cerebral Aβ load
There was no significant correlation (P > 0.05) detected between
ChT and age or CAMCOG-DS (Table 2). Although PET data were
only available for a subset of pwDS (n = 6, all male), Aβ load in the
medial orbitofrontal (MOF) and the rostral middle-frontal (RMF) cor-
tex showed a positive correlationwith all the sectors of the ETDRS grid
except for the SO, SI, and IO (MOF: r = 0.840 to 0.966 and RMF: r =
0.831 to 0.957) (Table 2). Figure 2 illustrates global ChT plotted against
Aβ load of theMOF and the RMF cortex. The global ChT remained sig-
nificant (P < 0.05) when the correlation was adjusted for the time of
the scan (AM/PM) and/or age (data not presented). A significant corre-
lation betweenChT andAβ load in other parts of the brain could not be
detected (data not shown).
In addition, the relationship between ChT and retinal thickness,
published earlier,9 was also assessed, and found no significant cor-
relation in any of the ETDRS grid sectors (P > 0.05) (data not
presented).
4 DISCUSSION
Identifying early, non-invasive and inexpensive biomarkers for proxy
outcome measure is crucial for the success of AD trials, especially
for those pwDS, as many are likely to benefit from treatment trials
aimed at preventing the onset of AD pathology. Choroidal thinning has
been proposed as an early biomarker for AD in the typically devel-
oping population.11–13 We conducted a detailed choroidal assessment
by extracting thickness values for each sector of the ETDRS grid. The
thicker choroid detected in our DS cohort with no signs of clinical
dementia does not mirror choroidal changes demonstrated in sAD and
MCI.11–13
Choroidal thickening due to increased vessel number in the
choroidal stroma was found in a post-mortem histological study of
sAD.14 The vascular proliferation could be the response to a metabolic
dysfunction of the retina due to retinal Aβ deposition.21,22
An increasing number of publications on post-mortem tissues show
Aβplaque-likedeposits in the retinaof donorswith sAD.23–27 However,
not all groups can verify these findings28–30 or can distinguish between
people with sAD and age-matched, cognitively normal controls.31
Only one study examined the presence of Aβ plaques in the retina of
pwDS using a modified laser scanning ophthalmoscope and curcumin
labeling.32 In the absence of controls, this study could not determine
the power of the method. Based on emerging data on sAD,24,33 the
need for further examination of retinal Aβ in vivo is warranted.
Wealso investigatedwhether the increasedChTmeasured in theDS
group could result from the SCS that was exclusively visible in pwDS.
We found no significant difference in ChT between those with or with-
out SCS. The SCSappears to be an age-related phenomenonmost likely
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F IGURE 2 Relationship between choroidal thickness and cerebral Aβ load. The scatter plots show the global choroidal thickness correlation
withmedial orbitofrontal (A) and rostral middle-frontal (B) cortex Aβ load. Unadjusted values are plotted, all cortical areas were analyzed, but only
the above two showed significant correlation. Abbreviations: MOF, medial orbitofrontal; RMF, rostral middle-frontal; Aβ, amyloid beta
due to fluid accumulation at the scleral and choroidal interface.34 It is
present in approximately 50%of typically developing individuals above
the age of 50 and is associated with hyperopia.34 The known acceler-
ated aging effect and the higher prevalence of refractive error (in par-
ticular, hyperopia) in pwDS may explain the exclusive presence of SCS
in the DS group.10,35
ChT is decreased in patients with systemic arterial hypertension
and may result from vascular contraction caused by high intravascu-
lar pressure in the choroid.36,37 A study on healthy volunteers aged
18 and 60 found an inverse relationship between systemic blood
pressure and sub-foveal ChT.38 Although blood pressure data were
not available for our cohort, DS is associated with lower systemic
blood pressure.39,40 Therefore, we speculate that the increased ChT
observed in our DS group might be, at least partially, due to lower sys-
temic and or choroidal blood pressure.
We have previously shown that a thicker retina was associated with
DS, and the thickening occurred in the inner retinal layers.9 pwDS have
amarkedly increased number of vessels in the retinal, which is believed
to be the consequence of altered angiogenesis in DS.41 Because retinal
vessels are present in the inner retinal layers, the higher vessel number
may contribute to the inner retinal layer changes.41 Therefore, apart
from the decreased blood pressure, the altered angiogenesis in pwDS
may also contributor to the increased ChT.
A recent study showed no significant increase in ChT in children
with DS,16 suggesting that the significantly thicker choroid detected
in our study is a feature of an older DS population. This raises the
question of whether the observed choroidal thickening in pwDS could
result fromdevelopingADpathology. Thepositive correlationbetween
ChT and the increased Aβ load in the MOF and RMS cortices could be
related to inflammatory changes observed in early AD stages.42 It is
perhaps not surprising that differences are associated with the frontal
cortices, as these areas are among the first that are affected by Aβ
deposition in pwDS.4 However, the results should not be overinter-
preted, considering the lownumberof studyparticipantswithPETdata
in this study and the lack of correlation with other primarily affected
areas such as the striatum.4
While information on choroidal changes are sparse,15 retinal thick-
ening had been reported in early stages of sporadic AD (preclinical AD
andMCI), and believed to be the result of inflammatory processes due
toADpathology.43,44 Hence, we cannot rule out the possibility that the
thickened choroid in our cohort is, at least partially, the result of inflam-
matory processes due to developing AD pathology.
We found thinner choroid in females compared to males in pwDS,
a difference that was not detected in the Ctrl group. The same het-
erogeneity in ChT between females and males has been observed in
the general population,45 and it is believed to be driven by hormonal
changes in postmenopausalwomen.46 Although the information on the
onset ofmenopause in our studywas not available, it iswell known that
themenopauseoccurs earlier in pwDSwomen than the general popula-
tion and is associatedwith an increased risk of dementia.47 Phenotypic
variability has been shown in sAD, and gender was a significant driv-
ing force.48 We are not aware of studies reporting gender-related phe-
notypic differences in choroidal or retinal thickness in pwDS or sAD.
Future studies assessing eye biomarkers for AD should consider gen-
der in study design based on our observation.
Decreased ChT had been associated with age.49 However, we did
not observe a significant age effect on ChT in the Ctrl or pwDS, prob-
ably due to the relatively young age and the limited age-range in our
study. Previous studies have also demonstrated a positive correlation
betweenChTand cognitive status in sADandMCI,11 but thiswas prob-
ably not detectable in our cohort due to the limited differences in cog-
nitive scores. Therefore, further studies should elucidate further this
relationship between ChT and cognitive measures in pwDS. Tan et al.
demonstrated that there are diurnal variations in ChT but this could
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also be influenced by refractive error, intraocular pressure (IOP), and
blood pressure.50 Although our analysis controlled for diurnal varia-
tion, refractive error, IOP and blood pressure data were not available.
We demonstrated a potential relationship between brain Aβ load and
ChT in a subset of pwDS (n = 6). However, further studies will need to
verify this relationship due to the small sample size andpossible gender
bias.
Oneof our study’s strengthswas the comprehensive analysis under-
taken by segmenting all the 25 OCT B-scans per posterior EDI scan,
which allowed us to extract data for each sector of the ETDRS grid. To
ensure that the manual choroidal segmentation was robust, we used a
second grader and found an excellent inter-observer agreement.
Overall, this study reports for the first time choroidal thickening
in adults with DS with no signs of clinical dementia. Further stud-
ies are needed with additional brain imaging components to elucidate
whether theobserved choroidal thickening in pwDS results fromdevel-
opingADpathology and/or a developmental aspect ofDS. Understand-
ing the cellular andmolecular changesunderpinning this thickeningwill
help gain better insight into early AD-related pathological changes in
pwDS. Imaging the choroid may provide a new understanding of how
to detect ormonitor disease progression and assess disease-modifying
interventions.
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STATEMENT OF SIGNIFICANCE
This is the first study that reports choroidal thickening in the eye in
adults with Down syndrome. This finding is in contrast to the thinning
observed in sporadic Alzheimer’s disease.
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